We believe personalized healthcare leads to better healthcare.
Genetic testing is revolutionizing how we approach standard care in the medical field. An individual can now obtain a personalized genetic blueprint that will educate the doctors in their community on how to specifically care for them. We aim to connect patients and their doctors with these genetic tests to improve and personalize their healthcare. Find out which genetic test would benefit you today.
DID YOU KNOW
Poor medication adherence takes the lives of over 125,000 Americans annually and costs the health care industry nearly $300 billion a year (Iuga, Aurel et al., 2014)
DID YOU KNOW
Drug-drug Interactions account for almost 4 percent of all emergency room visits (National Academy of Science, 1995).
DID YOU KNOW
Drug-drug Interactions cost the US healthcare system $136 billion annually (Johnson, JA et al.,1995).
FAQ TAB
What is Pharmacogenomics
Pharmacogenomics is the study of genetic variations that influence an individual’s response to drugs. Pharmacogenomics is the combination of pharmacology and genomics. Pharmacology is the part of science that study how drugs work. Genomics is the study of a person’s genome including the interactions of those genes with each other and with the person’s environment. Each person responds uniquely to treatment, while one treatment approach may work well for one individual, the same approach may not be effective or may cause adverse drug effects in other patients. The implementation of pharmacogenomics helps physicians make informed treatment decisions. This will lead to better outcomes by decreasing adverse drug events and by increasing the effectiveness of drugs.
When is pharmacogenomic testing indicated or recommended?
Pharmacogenomics testing predicts how individuals will respond to medication. It is recommended for any patient who is receiving or will receive medications that have pharmacogenomics biomarkers indicated in their labeling.
Pharmacogenomics testing is also recommended for poly pharmacy patients and any patient who is receiving drug treatment.
Do I have to be an expert in genetics to order the comprehensive test?
No. In fact, we are committed to providing intuitive tools for providers to use to make pharmacogenomic test results actionable. We also have clinical pharmacists on staff that are available for consultations to review results and answer your questions.
What medications are affected by the genes in the panel?
Results inform dosing recommendations for 220 commercial drugs. All 220 drugs are directly influenced by the pharmacogenomic genes tested, and carry pharmacogenomic recommendations put forth by the FDA, EMA, and/or CPIC.
View PharmGKB database of drugs with pharmacogenomics indications in their labeling.
https://www.pharmgkb.org/labels
How often should patients be tested?
Patients need only to be tested once, as genetic information does not change over time. Therefore, genetic testing results have lifetime utility.
Our Labs regularly add new medications to the comprehensive test. The labs will automatically regenerate a patient’s report at no extra cost to include new medications, assuming the genes and alleles associated with the medications were on our panel when the patient was tested.
If, however, the genes and alleles associated with the new medications were not on our panel when the patient was tested, they will not be included on regenerated reports. If you would like your patient to have newly added medications included in their report, a new order must be created and they must be tested again.
How long does it take to get the test results?
Pharmacogenomics test results will typically be available within 7-10 business days following receipt of the sample at our lab.
Cancer Genetic test results will typically be available in 3-4 weeks following receipt to the patient samples.
Billing codes
It is the responsibility of the submitting party to determine the correct billing codes to use when filing billing claims to third-party insurance. Below is a list of relevant codes.
GENE | CPT code | CPT code description |
---|---|---|
CYP1A2 | 81479 | Unlisted molecular pathology procedure |
CYP2B6 | 81479 | Unlisted molecular pathology procedure |
CYP2C19 | 81225 | Cyp2c19 gene common variants |
CYP2C9 | 81227 | Cyp2c9 gene common variants |
CYP2D6 | 81226 | Cyp2d6 gene common variants |
CYP3A4 | 81230 | Cyp3a4 gene common variants |
CYP3A5 | 81231 | Cyp3a5 gene common variants |
SLCO1B1 | 81328 | Slco1b1 gene common variants |
UGT1A1 | 81350 | Ugt1a1 gene |
CYP2B6 | 81479 | Unlisted molecular pathology procedure |
VKORC1 | 81355 | Vkorc1 gene |
F2 | 81240 | F2 gene |
NUDT15 | 81479 | Unlisted molecular pathology procedure |
F5 | 81241 | F5 gene |
OPRM1 | 81479 | Unlisted molecular pathology procedure |
COMT | 81479 | Unlisted molecular pathology procedure |
DRD2 | 81479 | Unlisted molecular pathology procedure |
HTR2C | 81479 | Unlisted molecular pathology procedure |
HTR2A | 81479 | Unlisted molecular pathology procedure |
DPYD | 81232 | Dpyd gene common variants |
GRIK4 | 81479 | Mopath procedure level 2 |
IL28B (IFNL4) | 81283 | Ifnl4 gene |
TPMT | 81335 | Tpmt gene common variants |
SLC6A4 | 81479 | Unlisted molecular pathology procedure |
SLC6A4 | 81479 | Unlisted molecular pathology procedure |
CYP2C Cluster | 81479 | Unlisted molecular pathology procedure |
CYP4F2 | 81479 | Unlisted molecular pathology procedure |
HLAA | 81381 | Hla i typing 1 allele hr |
HLAB | 81381 | Hla i typing 1 allele hr |
MTHFR | 81291 | Mthfr gene com variants |